Table 1.
Patient demographics n (%)
| All (n = 128) | Prophylaxis (n = 60) | Preemptive therapy (n = 68) | P value | |
| Age (yr) | 54 ± 10 | 52 ± 12 | 56 ± 8.5 | 0.04 |
| Sex | ||||
| Male | 90 (70) | 42 (70) | 48 (71) | 1.00 |
| Female | 38 (30) | 18 (30) | 20 (29) | |
| Weight (kg) | 80 ± 16 | 81 ± 13 | 79 ± 19 | 0.52 |
| SOFA | 9.1 ± 4.0 | 8.8 ± 3.8 | 9.4 ± 4.3 | 0.34 |
| APACHE II | 14.2 ± 6.7 | 13.3 ± 5.5 | 15.0 ± 7.5 | 0.13 |
| Lab. MELD at Transplantation | 18.5 ± 9.4 | 18.8 ± 8.8 | 18.2 ± 9.9 | 0.73 |
| CMV-status D/R | 0.24 | |||
| -/- | 19 (17) | 5 (10) | 14 (22) | |
| -/+ | 33 (29) | 16 (33) | 17 (27) | |
| +/+ | 60 (54) | 28 (57) | 32 (51) | |
| +/- | Excluded |
Data are expressed as mean ± SD or n (%). Complete CMV-status was unavailable for 16 patients, but was known not to be +/-. D/R: Donor/receptor; CMV: Cytomegalovirus; Lab.MELD: Model of end stage liver disease.